Affymetrix Supplies GeneChip® Technology to Veridex for Cancer Diagnostics Development
Affymetrix Inc. announced that it has granted Veridex, LLC, a Johnson & Johnson company, long-term and comprehensive access to its GeneChip(R) technology to create and market in-vitro diagnostics for cancer.
The agreement, made under the Powered by Affymetrix(TM) program, gives Veridex non-exclusive rights to Affymetrix’ patented arrays, instrumentation systems and planned improvements to these key technologies. Financial terms of the agreement were not disclosed.
“Microarrays are an important technology for clinical oncology in this era of molecular medicine,” said Robert Lipshutz, Senior Vice President Molecular Diagnostics and Emerging Markets at Affymetrix. “We are pleased that Veridex chose Affymetrix technology and believe that this continues to demonstrate that the leaders in the diagnostic field are choosing the Affymetrix platform for genetic analysis product development.”
Under the Powered by Affymetrix program, Affymetrix provides technology and expertise for products that are developed, branded and marketed by diagnostic companies. This includes the GeneChip System 3000Dx, which has been granted regulatory clearance by the U.S. Food and Drug Administration and CE marked in the European Union for in-vitro diagnostic use.
About Affymetrix:
Affymetrix scientists invented the world’s first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip® technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,000 systems have been installed around the world and nearly 3,000 peer-reviewed papers have been published using the technology. Affymetrix’ patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 900 employees worldwide.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.
